PLx Pharma (PLXP) Lifts IPO Registration Price

PLx Pharma Inc. (Nasdaq: PLXP) filed an amended registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $80.5 million, which compares with the original expectation of $20 million. The company plans to list on the Nasdaq under the ticker, PLXP.

Underwriters on the offering are Raymond James, Maxim Group, and Janney Montgomery Scott.

PLx Pharma is a late-stage specialty pharmaceutical company focused on developing our clinically validated and patent-protected PLxGuard delivery system to provide safer and more effective oral drugs for cardiovascular disease.

You May Also Be Interested In

• Worthington Enterprises raises dividend 5%, adds board member
• Selectis Health agrees to $5.75-per-share cash buyout by Black Pearl
• YZi Labs ends proxy fight with CEA Industries in board deal